Back to search results

Pilot Study of Dynamic Standing in Parkinson's Disease

This study is looking at how a special standing desk, called a Dynamic Standing Desk, might help people with Parkinson's disease. The desk gently moves to encourage small steps while you stand. Researchers want to see if using this desk improves how well you walk and your overall movement. This is a small, early-stage study (Phase 1) involving up to 5 participants. You might be able to join if you have Parkinson's disease and can stand and walk without help. The study will measure your walking speed and movement before and after using the desk for up to 6 weeks. The study is currently unclear on its recruitment status.

Study design
This is a small, early-stage (Phase 1) open-label study involving up to 5 participants.
What's involved
You would attend up to 12 four-hour sessions using the dynamic standing desk, plus a baseline and an outcome assessment, all within 6 weeks.
Compensation
Not stated in the trial record.
Follow-up
Your progress will be measured at baseline and up to 6 weeks after the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07543861

A Pilot Study of In-lab Dynamic Standing in Parkinson's Disease

Recruiting
PHASE1Ages 50+InterventionalTreatment
University of Michigan
~5 participants
Updated 2026-08-14 on ClinicalTrials.gov
What's tested:Dynamic Standing Desk

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Gait Speed
Measured over Baseline and post-intervention (up to 6 weeks).
+4 more outcomes measured

Conditions

Parkinson Disease

Explore related trials

Parkinson Disease

NCT07543861

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Domino's Farms

    Ann Arbor, Michiganstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Chatkaew Pongmala, PhD · PRINCIPAL_INVESTIGATOR · University of Michigan

Who to contact

Miriam Van Emde Boas, DPT
[email protected]
734-936-1174
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of Parkinson's Disease

Exclusion

Inability to stand or walk without an assistive device
History of symptoms in stance that preclude safe and comfortable participation, such as dizziness and lightheadedness, orthostasis, severe symptomatic leg or back musculoskeletal pain, or medication side effects
Any other history of medical or psychiatric comorbidity, precluding safe participation in the project.
History of symptomatic cardiovascular or pulmonary disease
History of active rheumatic arthritis
History of stroke or other neurologic conditions with significant residual sensorimotor deficits
History of disabling chronic pain syndrome requiring narcotic analgesics
Evidence of dementia (Mini Mental State Exam (or Montreal Cognitive Assessment test) \<24 and significant impairment in activities of daily living)
Venous ulcerative stasis or severe varicosities.
Pregnancy as determined by urine pregnancy test prior to DXA procedure in women of childbearing potential.

What this trial measures

  • Gait SpeedBaseline and post-intervention (up to 6 weeks).

    Gait speed will be measured during an 8.5-meter forward walking task measured in meters per second.

  • Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part IIIBaseline and post-intervention (up to 6 weeks).

    Clinical assessment that measures motor symptoms in Parkinson's Disease. Higher scores indicates more severe symptoms. Scores range from 0-132.

  • Montreal Cognitive AssessmentBaseline and post-intervention (up to 6 weeks).

    Clinical assessment that measures cognition. Higher scores indicate better cognition. Scores range from 0-30.

  • Timed Up and GoBaseline and post-intervention (up to 6 weeks).

    Clinical assessment that measures the time it takes for a participant to stand from a chair, walk 3 meters, turn around, walk back to the chair and sit back down. Higher time indicates increased motor impairment.

  • 5 Times Sit to StandBaseline and post-intervention (up to 6 weeks).

    Clinical assessment that measures the time it takes for a participant to sit and stand five times. Higher time indicates increased motor impairment.